1
|
Naushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, Pradhan S, Prakash S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Chandak GR, Lahiri A, Kar S, Mulay SR, Mugale MN, Srivastava M, Khan S, Srivastava A, Tomar B, Veerapandian M, Venkatachalam G, Vijayakumar SR, Agarwal A, Gupta D, Halami PM, Peddha MS, Sundaram GM, Veeranna RP, Pal A, Agarwal VK, Maurya AK, Singh RK, Raman AK, Anandasadagopan SK, Karuppanan P, Venkatesan S, Sardana HK, Kothari A, Jain R, Thakur A, Parihar DS, Saifi A, Kaur J, Kumar V, Mishra A, Gogeri I, Rayasam G, Singh P, Chakraborty R, Chaturvedi G, Karunakar P, Yadav R, Singhmar S, Singh D, Sarkar S, Bhattacharya P, Acharya S, Singh V, Verma S, Soni D, Seth S, Vashisht S, Thakran S, Fatima F, Singh AP, Sharma A, Sharma B, Subramanian M, Padwad YS, Hallan V, Patial V, Singh D, Tripude NV, Chakrabarti P, Maity SK, Ganguly D, Sarkar J, Ramakrishna S, Kumar BN, Kumar KA, Gandhi SG, Jamwal PS, Chouhan R, Jamwal VL, Kapoor N, Ghosh D, Thakkar G, Subudhi U, Sen P, Chaudhury SR, Kumar R, Gupta P, Tuli A, Sharma D, Ringe RP, D A, Kulkarni M, Shanmugam D, et alNaushin S, Sardana V, Ujjainiya R, Bhatheja N, Kutum R, Bhaskar AK, Pradhan S, Prakash S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Chandak GR, Lahiri A, Kar S, Mulay SR, Mugale MN, Srivastava M, Khan S, Srivastava A, Tomar B, Veerapandian M, Venkatachalam G, Vijayakumar SR, Agarwal A, Gupta D, Halami PM, Peddha MS, Sundaram GM, Veeranna RP, Pal A, Agarwal VK, Maurya AK, Singh RK, Raman AK, Anandasadagopan SK, Karuppanan P, Venkatesan S, Sardana HK, Kothari A, Jain R, Thakur A, Parihar DS, Saifi A, Kaur J, Kumar V, Mishra A, Gogeri I, Rayasam G, Singh P, Chakraborty R, Chaturvedi G, Karunakar P, Yadav R, Singhmar S, Singh D, Sarkar S, Bhattacharya P, Acharya S, Singh V, Verma S, Soni D, Seth S, Vashisht S, Thakran S, Fatima F, Singh AP, Sharma A, Sharma B, Subramanian M, Padwad YS, Hallan V, Patial V, Singh D, Tripude NV, Chakrabarti P, Maity SK, Ganguly D, Sarkar J, Ramakrishna S, Kumar BN, Kumar KA, Gandhi SG, Jamwal PS, Chouhan R, Jamwal VL, Kapoor N, Ghosh D, Thakkar G, Subudhi U, Sen P, Chaudhury SR, Kumar R, Gupta P, Tuli A, Sharma D, Ringe RP, D A, Kulkarni M, Shanmugam D, Dharne MS, Dastager SG, Joshi R, Patil AP, Mahajan SN, Khan AH, Wagh V, Yadav RK, Khilari A, Bhadange M, Chaurasiya AH, Kulsange SE, Khairnar K, Paranjape S, Kalita J, Sastry NG, Phukan T, Manna P, Romi W, Bharali P, Ozah D, Sahu RK, Babu EVSSK, Sukumaran R, Nair AR, Valappil PK, Puthiyamadam A, Velayudhanpillai A, Chodankar K, Damare S, Madhavi Y, Aggarwal VV, Dahiya S, Agrawal A, Dash D, Sengupta S. Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2. eLife 2021; 10:e66537. [PMID: 33876727 PMCID: PMC8118652 DOI: 10.7554/elife.66537] [Show More Authors] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Accepted: 04/09/2021] [Indexed: 12/14/2022] Open
Abstract
To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001).
Collapse
|
Multicenter Study |
4 |
17 |
2
|
Singh P, Ujjainiya R, Prakash S, Naushin S, Sardana V, Bhatheja N, Singh AP, Barman J, Kumar K, Gayali S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Lahiri A, Kar S, Bhosale V, Srivastava M, Mugale MN, Pandey CP, Khan S, Katiyar S, Raj D, Ishteyaque S, Khanka S, Rani A, Promila, Sharma J, Seth A, Dutta M, Saurabh N, Veerapandian M, Venkatachalam G, Bansal D, Gupta D, Halami PM, Peddha MS, Veeranna RP, Pal A, Singh RK, Anandasadagopan SK, Karuppanan P, Rahman SN, Selvakumar G, Venkatesan S, Karmakar MK, Sardana HK, Kothari A, Parihar DS, Thakur A, Saifi A, Gupta N, Singh Y, Reddu R, Gautam R, Mishra A, Mishra A, Gogeri I, Rayasam G, Padwad Y, Patial V, Hallan V, Singh D, Tirpude N, Chakrabarti P, Maity SK, Ganguly D, Sistla R, Balthu NK, A KK, Ranjith S, Kumar BV, Jamwal PS, Wali A, Ahmed S, Chouhan R, Gandhi SG, Sharma N, Rai G, Irshad F, Jamwal VL, Paddar MA, Khan SU, Malik F, Ghosh D, Thakkar G, Barik SK, Tripathi P, Satija YK, Mohanty S, Khan MT, Subudhi U, Sen P, Kumar R, Bhardwaj A, Gupta P, Sharma D, Tuli A, Ray Chaudhuri S, Krishnamurthi S, et alSingh P, Ujjainiya R, Prakash S, Naushin S, Sardana V, Bhatheja N, Singh AP, Barman J, Kumar K, Gayali S, Khan R, Rawat BS, Tallapaka KB, Anumalla M, Lahiri A, Kar S, Bhosale V, Srivastava M, Mugale MN, Pandey CP, Khan S, Katiyar S, Raj D, Ishteyaque S, Khanka S, Rani A, Promila, Sharma J, Seth A, Dutta M, Saurabh N, Veerapandian M, Venkatachalam G, Bansal D, Gupta D, Halami PM, Peddha MS, Veeranna RP, Pal A, Singh RK, Anandasadagopan SK, Karuppanan P, Rahman SN, Selvakumar G, Venkatesan S, Karmakar MK, Sardana HK, Kothari A, Parihar DS, Thakur A, Saifi A, Gupta N, Singh Y, Reddu R, Gautam R, Mishra A, Mishra A, Gogeri I, Rayasam G, Padwad Y, Patial V, Hallan V, Singh D, Tirpude N, Chakrabarti P, Maity SK, Ganguly D, Sistla R, Balthu NK, A KK, Ranjith S, Kumar BV, Jamwal PS, Wali A, Ahmed S, Chouhan R, Gandhi SG, Sharma N, Rai G, Irshad F, Jamwal VL, Paddar MA, Khan SU, Malik F, Ghosh D, Thakkar G, Barik SK, Tripathi P, Satija YK, Mohanty S, Khan MT, Subudhi U, Sen P, Kumar R, Bhardwaj A, Gupta P, Sharma D, Tuli A, Ray Chaudhuri S, Krishnamurthi S, Prakash L, Rao CV, Singh BN, Chaurasiya A, Chaurasiyar M, Bhadange M, Likhitkar B, Mohite S, Patil Y, Kulkarni M, Joshi R, Pandya V, Mahajan S, Patil A, Samson R, Vare T, Dharne M, Giri A, Mahajan S, Paranjape S, Sastry GN, Kalita J, Phukan T, Manna P, Romi W, Bharali P, Ozah D, Sahu RK, Dutta P, Singh MG, Gogoi G, Tapadar YB, Babu EV, Sukumaran RK, Nair AR, Puthiyamadam A, Valappil PK, Pillai Prasannakumari AV, Chodankar K, Damare S, Agrawal VV, Chaudhary K, Agrawal A, Sengupta S, Dash D. A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys. Comput Biol Med 2022; 146:105419. [PMID: 35483225 PMCID: PMC9040372 DOI: 10.1016/j.compbiomed.2022.105419] [Show More Authors] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 02/19/2022] [Accepted: 02/19/2022] [Indexed: 12/16/2022]
Abstract
Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the vaccine effectiveness. Asymptomatic breakthrough infections have been a major problem in assessing vaccine effectiveness in populations globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines since whole virion vaccines generate antibodies against all the viral proteins. Here, we show how a statistical and machine learning (ML) based approach can be used to discriminate between SARS-CoV-2 infection and immune response to an inactivated whole virion vaccine (BBV152, Covaxin). For this, we assessed serial data on antibodies against Spike and Nucleocapsid antigens, along with age, sex, number of doses taken, and days since last dose, for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, our ensemble ML model classified 724 to be infected. For method validation, we determined the relative ability of a random subset of samples to neutralize Delta versus wild-type strain using a surrogate neutralization assay. We worked on the premise that antibodies generated by a whole virion vaccine would neutralize wild type more efficiently than delta strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, neutralization against Delta strain was more effective, indicating infection. We found 71.8% subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period. Our approach will help in real-world vaccine effectiveness assessments where whole virion vaccines are commonly used.
Collapse
|
research-article |
3 |
9 |